Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-analysis of DNA methylation aging signatures in 17 human tissues.

Nature aging·2026
Same author

Effect of Age and Sex on Lower Extremity Power Production Capacity Throughout the Lifespan Based on 30 217 Finnish Participant Data.

Scandinavian journal of medicine & science in sports·2026
Same author

Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights.

The Journal of pathology·2026
Same author

Feasibility of a field-based submaximal stair ascent test for estimating aerobic capacity and lower-limb strength in middle-aged and older adults.

Clinical physiology and functional imaging·2026
Same author

Evaluation of Genetics in the Association Between Cardiorespiratory Fitness and Health: Insights from a Genome-Wide Polygenic Score for Cardiorespiratory Fitness in the FinnGen and HUNT cohorts.

Scandinavian journal of medicine & science in sports·2026
Same author

Sex-Based Differences in Circulating microRNA and Metabolite Signatures Associated with Physical Activity in Lynch Syndrome Carriers.

Cancer prevention research (Philadelphia, Pa.)·2026

Related Experiment Video

Updated: Jun 29, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.7K

Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome-A Pilot Study.

Tero Sievänen1, Tiina Jokela1, Matti Hyvärinen1

  • 1Gerontology Research Center and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

Cancer Prevention Research (Philadelphia, Pa.)
|March 29, 2024
PubMed
Summary

A new circulating microRNA (c-miR) signature can predict Lynch syndrome (LS) cancer incidence within four years. This biomarker also correlates with body mass index (BMI), offering insights into cancer risk management.

More Related Videos

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

Related Experiment Videos

Last Updated: Jun 29, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.7K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

Area of Science:

  • Oncology
  • Genetics
  • Biomarkers

Background:

  • Lynch syndrome (LS) is an autosomal dominant cancer predisposition with high genetic risk.
  • Lifestyle factors significantly modify cancer risk in LS patients.
  • Effective cancer risk prediction models are crucial for improving LS patient survival.

Purpose of the Study:

  • To investigate a circulating microRNA (c-miR) signature for predicting LS cancer incidence.
  • To explore the correlation between the c-miR signature and lifestyle risk factors.
  • To develop and validate a predictive model for LS cancer risk.

Main Methods:

  • Analysis of 110 c-miR samples from LS carriers over a 4-year prospective surveillance period.
  • Utilized Lasso regression to identify cancer-predicting c-miRs.
  • Developed a predictive model based on c-miR risk score and validated using 5-fold cross-validation.
  • Assessed correlations between c-miR risk score and lifestyle factors (physical activity, BMI, diet, NSAID usage).

Main Results:

  • Identified five c-miRs (hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-200a-3p, hsa-miR-3613-5p, hsa-miR-3615) as cancer predictors.
  • The c-miR risk score significantly predicted LS cancer incidence (HR 2.72, C-index = 0.72), with cross-validation yielding an average C-index of 0.75.
  • The c-miR risk score showed a correlation with body mass index (BMI) (r = 0.23, P < 0.01).

Conclusions:

  • A specific c-miR signature can predict Lynch syndrome cancer incidence within a 4-year timeframe.
  • The identified c-miR signature is associated with BMI, suggesting a link between lifestyle and molecular risk prediction.
  • This pilot study provides a novel serum miRNA-based risk prediction model for LS, warranting further validation.